The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis
Open accessAbstract
BACKGROUND: Mortality among patients with severe acute alcoholic hepatitis is high, even among those treated with glucocorticoids. We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS: We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). All patients received 4 weeks of prednisolone. The prednisolone-N-acetylcysteine group received intravenous N-acetylcysteine on day 1 (at a dose of 150, 50, and 100 mg per kilogram of body weight in 250, 500, and 1000 ml of 5% glucose solution over a period of 30 minutes, 4 hours, and 16 hours, respectively) and on days 2 through 5 (100 mg per kilogram per day in 1000 ml of 5% glucose solution). The prednisolone-only group received an infusion in 1000 ml of 5% glucose solution per day on days 1 through 5. The primary outcome was 6-month survival. Secondary outcomes included survival at 1 and 3 months, hepatitis complications, adverse events related to N-acetylcysteine use, and changes in bilirubin levels on days 7 and 14. RESULTS: Mortality was not significantly lower in the prednisolone-N-acetylcysteine group than in the prednisolone-only group at 6 months (27% vs. 38%, P = 0.07). Mortality was significantly lower at 1 month (8% vs. 24%, P = 0.006) but not at 3 months (22% vs. 34%, P = 0.06). Death due to the hepatorenal syndrome was less frequent in the prednisolone-N-acetylcysteine group than in the prednisolone-only group at 6 months (9% vs. 22%, P = 0.02). In a multivariate analysis, factors associated with 6-month survival were a younger age (P<0.001), a shorter prothrombin time (P<0.001), a lower level of bilirubin at baseline (P<0.001), and a decrease in bilirubin on day 14 (P<0.001). Infections were less frequent in the prednisolone-N-acetylcysteine group than in the prednisolone-only group (P = 0.001); other side effects were similar in the two groups. CONCLUSIONS: Although combination therapy with prednisolone plus N-acetylcysteine increased 1-month survival among patients with severe acute alcoholic hepatitis, 6-month survival, the primary outcome, was not improved. (Funded by Programme Hospitalier de Recherche Clinique; AAH-NAC ClinicalTrials.gov number, NCT00863785 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aruoma, O. I., Halliwell, B., Hoey, B. M., & Butler, J. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90066-x · Cited by 1,772
The alcohol use disorders identification test: an update of research findings
Reinert, D. F., & Allen, J. P. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00295.x · Cited by 1,397 · cited 1×
“Relapse of alcohol use after 1 month 15 (17) 15 (18)”
BackgroundO'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Early Liver Transplantation for Severe Alcoholic Hepatitis
Mathurin, P., Moreno, C., Samuel, D., Dumortier, J., Salleron, J., Durand, F., Castel, H., Duhamel, A., Pageaux, G.-P., Leroy, V., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105703 · Cited by 960
Corticosteroid therapy of alcoholic hepatitis
Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Mezey, E., & White, R. I. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90401-8 · Cited by 925
Lee, W. M., Hynan, L. S., Rossaro, L., Fontana, R. J., Stravitz, R. T., Larson, A. M., Davern, T. J., Murray, N. G., McCashland, T., Reisch, J. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.006 · Cited by 607
Fox, M. P., & Rosen, S. (2010) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2010.02508.x · Cited by 559
Carithers, R. L., Herlong, H. F., Diehl, A. M., Shaw, E. W., Combes, B., Fallon, H. J., & Maddrey, W. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-9-685 · Cited by 504
The CAGE Questionnaire for Alcohol Misuse: A Review of Reliability and Validity Studies
Dhalla, S., & Kopec, J. A. (2007) · Clinical and Investigative Medicine · doi:10.25011/cim.v30i1.447 · Cited by 500
TREATMENT OF PARACETAMOL (ACETAMINOPHEN) POISONING WITH N-ACETYLCYSTEINE
Prescott, L. F., Ballantyne, A., Proudfoot, A. T., Park, J., & Adriaenssens, P. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90612-2 · Cited by 460
Cited by
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Alcoholic liver disease: mechanisms of injury and targeted treatment
Louvet, A., & Mathurin, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.35 · Cited by 855
ACG Clinical Guideline: Alcoholic Liver Disease
Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.469 · Cited by 835
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Thursz, M. R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C. P., Downs, N., Gleeson, D., MacGilchrist, A., Grant, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412278 · Cited by 769
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720
Acute-on chronic liver failure
Jalan, R., Gines, P., Olson, J. C., Mookerjee, R. P., Moreau, R., Garcia-Tsao, G., Arroyo, V., & Kamath, P. S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.026 · Cited by 646
N-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
Acute-on-chronic liver failure in cirrhosis
Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U., García-Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 434
Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review
Singal, A. K., & Mathurin, P. (2021) · JAMA · doi:10.1001/jama.2021.7683 · Cited by 398
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Acute-on-chronic liver failure
Bernal, W., Jalan, R., Quaglia, A., Simpson, K., Wendon, J., & Burroughs, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00309-8 · Cited by 331
Zebrafish: An Important Tool for Liver Disease Research
Goessling, W., & Sadler, K. C. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.034 · Cited by 323
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Trends in the management and burden of alcoholic liver disease
Mathurin, P., & Bataller, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.006 · Cited by 288
“24%) and incidence of hepatorenal syndrome and infection [94].”
BackgroundBataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
Bartneck, M., Scheyda, K. M., Warzecha, K. T., Rizzo, L. Y., Hittatiya, K., Luedde, T., Storm, G., Trautwein, C., Lammers, T., & Tacke, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.030 · Cited by 141
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Mandrekar, P., Bataller, R., Tsukamoto, H., & Gao, B. (2016) · Hepatology · doi:10.1002/hep.28530 · Cited by 115
“A recent study has shown some beneficial effects of N-acetylcysteine, a potent but cell-impermeant antioxidant.((13)) Unfortunately, many patients do not respond to prednisolone; thus, novel targeted therapies are urgently needed.”
BackgroundPharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, C. L., Halse, M., Leggio, L., Fricchione, S. B., Brickley, M., Haass-Koffler, C. L., Tavares, T., Swift, R. M., & Kenna, G. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140028 · Cited by 51
Pathogenesis of Alcohol-Associated Liver Disease
Mandrekar, P., & Mandal, A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.005 · Cited by 34
Metadata
- Authors
- Nguyen-Khac, E., Thevenot, T., Piquet, M.-A., Benferhat, S., Goria, O., Chatelain, D., Tramier, B., Dewaele, F., Ghrib, S., Rudler, M., Carbonell, N., Tossou, H., Bental, A., Bernard-Chabert, B., & Dupas, J.-L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-11-10
- Volume
- 365
- Issue
- 19
- Pages
- 1781-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981368166
- Cited by
- 410
- References
- 42
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.